Jointown Pharmaceutical Group Future Growth
Future criteria checks 1/6
Jointown Pharmaceutical Group is forecast to grow earnings and revenue by 18.9% and 12.3% per annum respectively. EPS is expected to grow by 16.5% per annum. Return on equity is forecast to be 11.7% in 3 years.
Key information
18.9%
Earnings growth rate
16.5%
EPS growth rate
Healthcare earnings growth | 21.5% |
Revenue growth rate | 12.3% |
Future return on equity | 11.7% |
Analyst coverage | Low |
Last updated | 27 Jun 2024 |
Recent future growth updates
Recent updates
These 4 Measures Indicate That Jointown Pharmaceutical Group (SHSE:600998) Is Using Debt Reasonably Well
Aug 01Jointown Pharmaceutical Group (SHSE:600998) Has More To Do To Multiply In Value Going Forward
Jun 07Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Earnings Are Not Doing Enough For Some Investors
May 21Calculating The Intrinsic Value Of Jointown Pharmaceutical Group Co., Ltd (SHSE:600998)
Apr 05Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 208,908 | 3,750 | N/A | -519 | 3 |
12/31/2025 | 189,211 | 3,160 | N/A | 6,019 | 5 |
12/31/2024 | 168,312 | 2,759 | N/A | -11,387 | 4 |
3/31/2024 | 148,519 | 2,151 | 3,155 | 4,116 | N/A |
12/31/2023 | 150,140 | 2,174 | 3,699 | 4,748 | N/A |
9/30/2023 | 151,842 | 2,170 | 5,217 | 6,257 | N/A |
6/30/2023 | 151,797 | 2,159 | 5,409 | 6,559 | N/A |
3/31/2023 | 147,366 | 2,194 | 2,395 | 3,611 | N/A |
12/31/2022 | 140,424 | 2,085 | 2,743 | 3,986 | N/A |
9/30/2022 | 133,260 | 1,782 | 3,638 | 4,886 | N/A |
6/30/2022 | 128,411 | 1,545 | 1,345 | 2,656 | N/A |
3/31/2022 | 124,929 | 2,141 | 1,862 | 3,234 | N/A |
12/31/2021 | 122,407 | 2,448 | 2,073 | 3,459 | N/A |
9/30/2021 | 122,634 | 3,339 | 282 | 1,907 | N/A |
6/30/2021 | 121,491 | 3,988 | 3,113 | 4,802 | N/A |
3/31/2021 | 116,315 | 3,258 | 2,009 | 3,574 | N/A |
12/31/2020 | 110,860 | 3,075 | 1,987 | 3,444 | N/A |
9/30/2020 | 106,438 | 2,849 | 2,930 | 4,117 | N/A |
6/30/2020 | 102,417 | 2,242 | 2,025 | 3,152 | N/A |
3/31/2020 | 102,007 | 1,976 | 2,349 | 3,480 | N/A |
12/31/2019 | 99,497 | 1,727 | 1,576 | 2,768 | N/A |
9/30/2019 | 96,769 | 1,588 | 1,479 | 2,737 | N/A |
6/30/2019 | 93,116 | 1,547 | 1,882 | 3,123 | N/A |
3/31/2019 | 89,589 | 1,446 | 583 | 1,833 | N/A |
12/31/2018 | 87,136 | 1,341 | -593 | 1,222 | N/A |
9/30/2018 | 83,230 | 1,262 | -1,949 | -231 | N/A |
6/30/2018 | 80,163 | 1,189 | -3,942 | -2,213 | N/A |
3/31/2018 | 77,339 | 1,481 | -3,956 | -2,221 | N/A |
12/31/2017 | 73,943 | 1,446 | N/A | -1,012 | N/A |
9/30/2017 | 70,783 | 1,374 | N/A | -2,586 | N/A |
6/30/2017 | 67,999 | 1,360 | N/A | -198 | N/A |
3/31/2017 | 64,925 | 921 | N/A | 1,382 | N/A |
12/31/2016 | 61,557 | 877 | N/A | 431 | N/A |
9/30/2016 | 58,367 | 777 | N/A | 1,748 | N/A |
6/30/2016 | 55,482 | 754 | N/A | 193 | N/A |
3/31/2016 | 53,091 | 718 | N/A | -783 | N/A |
12/31/2015 | 49,589 | 695 | N/A | 436 | N/A |
9/30/2015 | 46,895 | 640 | N/A | -1,088 | N/A |
6/30/2015 | 45,049 | 602 | N/A | -1,287 | N/A |
3/31/2015 | 43,171 | 566 | N/A | -312 | N/A |
12/31/2014 | 41,068 | 561 | N/A | -172 | N/A |
9/30/2014 | 39,273 | 533 | N/A | -450 | N/A |
6/30/2014 | 37,189 | 509 | N/A | -702 | N/A |
3/31/2014 | 35,150 | 493 | N/A | -1,230 | N/A |
12/31/2013 | 33,438 | 478 | N/A | 138 | N/A |
9/30/2013 | 32,097 | 464 | N/A | -1,105 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600998's forecast earnings growth (18.9% per year) is above the savings rate (2.9%).
Earnings vs Market: 600998's earnings (18.9% per year) are forecast to grow slower than the CN market (22.2% per year).
High Growth Earnings: 600998's earnings are forecast to grow, but not significantly.
Revenue vs Market: 600998's revenue (12.3% per year) is forecast to grow slower than the CN market (13.7% per year).
High Growth Revenue: 600998's revenue (12.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600998's Return on Equity is forecast to be low in 3 years time (11.7%).